> Details

Hackstein, Holger; Amoros, Jose Jaime Verdu; Bein, Gregor; Woessmann, Wilhelm

Successful use of miniphotopheresis for the treatment of graft‐versus‐host disease

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Successful use of miniphotopheresis for the treatment of graft‐versus‐host disease
  • Contributor: Hackstein, Holger; Amoros, Jose Jaime Verdu; Bein, Gregor; Woessmann, Wilhelm
  • imprint: Wiley, 2014
  • Published in: Transfusion
  • Language: English
  • DOI: 10.1111/trf.12596
  • ISSN: 0041-1132; 1537-2995
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Background</jats:title><jats:p>Extracorporeal photopheresis (<jats:styled-content style="fixed-case">ECP</jats:styled-content>) is an important cell‐based therapy for graft‐versus‐host disease (<jats:styled-content style="fixed-case">GVHD</jats:styled-content>); however, the blood volume required per treatment to achieve a clinical response is unknown.</jats:p></jats:sec><jats:sec><jats:title>Study Design and Methods</jats:title><jats:p>We developed a mini‐<jats:styled-content style="fixed-case">ECP</jats:styled-content> technique (mini‐<jats:styled-content style="fixed-case">ECP</jats:styled-content>) using only 100 to 200 <jats:styled-content style="fixed-case">mL</jats:styled-content> of whole blood for patients with contraindications for apheresis or low body weight. Sixteen patients (n = 13 acute, n = 3 chronic <jats:styled-content style="fixed-case">GVHD</jats:styled-content>) with a median body weight of 19 kg (range, 7‐48 kg) received 460 mini‐<jats:styled-content style="fixed-case">ECP</jats:styled-content> treatments with a median duration of 115 days (range, 49‐973 days).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Mini‐<jats:styled-content style="fixed-case">ECP</jats:styled-content> was well tolerated, and acute <jats:styled-content style="fixed-case">GVHD</jats:styled-content> resolved completely in nine of 13 patients and partially in two patients but not in two patients. Cutaneous chronic <jats:styled-content style="fixed-case">GVHD</jats:styled-content> exhibited a mixed response (one complete, one partial, and one no response).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>These results indicate mini‐<jats:styled-content style="fixed-case">ECP</jats:styled-content> as a novel and less invasive therapy for patients with <jats:styled-content style="fixed-case">GVHD</jats:styled-content> and contraindications for apheresis.</jats:p></jats:sec>